Wednesday - February 18, 2026

Category Archives: Science

Global Medical Aesthetics Market to Reach USD 40.70 Billion by 2031, Driven by Surge in Minimally Invasive Procedures

Global Medical Aesthetics Market by Product (Botox, Filler, Peel, Liposuction, Microneedling, Hair Removal, Laser Resurfacing, RF, Phototherapy), Procedure (Surgical, Non-surgical), End User (Hospital, Beauty Clinic, Spa), and Region – Global Forecast to 2031 According to a new research report titled … Continue reading →

Breast Cancer Clinical Trial Pipeline Expands as 250+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 250+ Breast Cancer companies and 300+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It … Continue reading →

Gastroenteropancreatic Neuroendocrine Tumors Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Gastroenteropancreatic Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumors market trends in the United States, EU4 (Germany, … Continue reading →

NSCLC Clinical Trial Pipeline Shows Potential with Active Contributions from 100+ Key Companies | DelveInsight

DelveInsight’s “NSCLC Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the NSCLC pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline … Continue reading →

Malignant Pleural Effusion Clinical Trial Pipeline Gains Momentum: 8+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Malignant Pleural Effusion Pipeline Insight” report provides comprehensive global coverage of pipeline therapies for Malignant Pleural Effusion across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting … Continue reading →

Familial Chylomicronemia Syndrome Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Familial Chylomicronemia Syndrome Pipeline Insight” report provides comprehensive global coverage of pipeline therapies for Familial Chylomicronemia Syndrome across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting … Continue reading →

What Are Tan Delta Test Acceptable Values for Electrical Insulation Quality Assurance?

The image is Wrindu Tan Delta Tester. Wrindu, a leading global manufacturer and supplier of high-precision electrical insulation testing equipment for OEM and wholesale markets, has released comprehensive expert guidance on Tan Delta test acceptable values and best practices—an essential … Continue reading →

B-Cell Lymphoma Treatment Pipeline Shows Strong Momentum as 295+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “B-cell Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Glioblastoma Clinical Trial Pipeline Accelerates as 200+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Glioblastoma Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics … Continue reading →